The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.

Abstract

OBJECTIVE:

As an ever widening array of anti-hyperglycemic agents are now available, the effect of these drugs on lipids is increasingly complex and controversial. The present meta-analysis was designed to clarify the effect of a dual combination of noninsulin anti-hyperglycemic agents on lipids in type 2 diabetes.

METHODS:

Randomized controlled trials comparing different dual combinations of antidiabetic drugs were identified by searching PubMed, Cochrane Library, and Embase. Study selection, data abstraction and quality assessment were carried out by two reviewers independently. Change in low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride and total cholesterol were pooled by both traditional meta-analysis and network meta-analysis.

RESULTS:

Eighteen studies with a total of 10,222 patients were included. Network meta-analysis suggested that metformin + dipeptidyl peptidase-4 inhibitors (DPP-4) (LDL cholesterol: -0.19 mmol/L; HDL cholesterol: 0.06 mmol/L; triglycerides: -0.73 mmol/L; total cholesterol: -0.4 mmol/L) and metformin + glucagon-like peptide-1 (GLP-1) agonist (LDL cholesterol: -0.3 mmol/L; HDL cholesterol: 0.06 mmol/L; triglycerides: -0.64 mmol/L; total cholesterol: -0.5 mmol/L) were associated with relatively larger beneficial effects on the lipid profile among all combinations. Compared with metformin + thiazolidinedione, metformin + GLP-1 agonist (mean difference: -0.38; 95% confidence interval [CI]: -0.66 to -0.10) significantly decreased LDL cholesterol. Metformin + thiazolidinedione showed a larger increase than metformin + sulfonylurea in HDL cholesterol (mean difference: 0.1; 95% CI: 0.01 to 0.21).

CONCLUSIONS:

The effect of a dual combination of noninsulin anti-hyperglycemic agents on lipids is moderate to small, with metformin + DPP-4 inhibitor and metformin + GLP-1 agonist showing consistent beneficial effects on LDL cholesterol, HDL cholesterol, triglycerides and total cholesterol. Future trials are needed to confirm these findings.

• Authors: Xiaoyu Dai, Hongtao Wang, Zhong Jing, Ping Fu
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 30 Issue 9 Pg. 1777-86 (Sep 2014) ISSN: 1473-4877 [Electronic] England
• PMID: 24805140 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)

Chemical References

• Biomarkers
• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Lipoproteins, HDL
• Lipoproteins, LDL
• Sulfonylurea Compounds
• Thiazolidinediones
• Triglycerides
• Glucagon-Like Peptide 1
• Metformin
• Cholesterol
• 2,4-thiazolidinedione

Topics

• Biomarkers (blood)
• Cholesterol (blood)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Drug Therapy, Combination
• Glucagon-Like Peptide 1 (agonists)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Lipoproteins, HDL (blood)
• Lipoproteins, LDL (blood)
• Metformin (therapeutic use)
• Models, Statistical
• Randomized Controlled Trials as Topic
• Sulfonylurea Compounds (therapeutic use)
• Thiazolidinediones (therapeutic use)
• Treatment Outcome
• Triglycerides (blood)